# Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

> **NCT05482334** · PHASE2 · WITHDRAWN · sponsor: **University of Colorado, Denver**

## Conditions studied

- Down Syndrome

## Interventions

- **DRUG:** Sargramostim for Injection
- **DRUG:** Saline Placebo

## Key facts

- **NCT ID:** NCT05482334
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-10-23
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficulties enrolling participants due to study design
- **Last updated:** 2025-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05482334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05482334, "Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05482334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*